Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 8192150, 6 pages
https://doi.org/10.1155/2017/8192150
Review Article

Metastatic Crohn’s Disease: An Approach to an Uncommon but Important Cutaneous Disorder

1Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
2Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
3Departments of Medicine and Pediatrics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

Correspondence should be addressed to Jessica Howard; moc.liamg@drawoh.acissej.rd

Received 17 August 2016; Accepted 7 December 2016; Published 3 January 2017

Academic Editor: Arjen F. Nikkels

Copyright © 2017 Babak Aberumand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To provide physicians with a clinical approach to metastatic Crohn’s disease (MCD). Main Message. Metastatic Crohn’s disease, defined as skin lesions present in areas noncontiguous with the gastrointestinal tract, is the rarest cutaneous manifestation of Crohn’s disease. MCD lesions vary in morphology and can arise anywhere on the skin. MCD presents equally in both sexes and across age groups. Cutaneous findings may precede, develop concurrently with, or follow gastrointestinal involvement. A detailed history and thorough physical examination including a full-skin exam may help to exclude other dermatoses, as MCD can mimic other common disorders. A biopsy is required for a definitive diagnosis. Treatment options for MCD remain underwhelming due to the lack of randomized control studies and varying responses of reported therapeutic methods. Topical, intralesional, and systemic corticosteroids, antibiotics, traditional immunosuppressants, and surgery have shown mixed results. Recently, biologics have shown promise, even with refractory cases of MCD. Conclusion. MCD is an important cutaneous manifestation of this inflammatory disorder. Although a rare entity, early recognition can provide opportunity for successful therapeutic intervention.